Posted by Michael Wonder on 22 Aug 2018
Agenda for the November 2018 PBAC meeting
22 August 2018 - The agenda for the November 2018 PBAC meeting is now available.
The PBAC will consider 51 submissions (30 major & 21 minor) at its next scheduled meeting in November. 44/51 (86%) are for a PBS medicine/vaccine/gene therapy, 3 (6%) are for a PBS medicinal preparation and 4 (8%) are for a NIP vaccine.
The Committee will also consider five reports from the Drug Utilisation Subcommittee for medicines for:
- Ovarian cancer (1 medicine)
- Hepatitis C virus infection (8 medicines)
- Gout (1 medicine)
- Myelofibrosis (1 medicine)
- Pulmonary arterial hypertension (8 medicine)
11 (22%) of the 51 submissions are for a new medicine.
11 (22%) of the 51 submissions are resubmissions; most are for a new medicine or a new indication.
Just under a quarter of all submissions are for oncology medicines.
MSD is the leading applicant with 5 submissions (3 major, 2 minor). Pfizer has lodged 4 submissions (all major) and Amgen, Seqirus and Ipsen have each lodged 3 submissions.
Further insights from the agenda will appear in tomorrow's edition of MAESTrO Daily.
